The Gross Margin of Regeneron Pharmaceuticals, Inc. (REGN) is
86.56%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
86.56%
|
| 2024-12-31 |
87.01%
|
| 2023-12-31 |
86.94%
|
| 2022-12-31 |
89.31%
|
| 2021-12-31 |
86.28%
|
| 2020-12-31 |
86.82%
|
| 2019-12-31 |
90.05%
|
| 2018-12-31 |
93.53%
|
| 2017-12-31 |
93.24%
|
| 2016-12-31 |
93.83%
|
| Ticker |
Name |
Value |
|
ALKS
|
Alkermes Plc
|
86.69%
|
|
ALNY
|
Alnylam Pharmaceuticals, Inc.
|
81.64%
|
|
BPMC
|
Blueprint Medicines Corp
|
96.04%
|
|
CRSP
|
CRISPR Therapeutics AG
|
7775.20%
|
|
ASND
|
Ascendis Pharma A/S
|
86.82%
|
|
INCY
|
Incyte Corp
|
93.26%
|
|
KOD
|
Kodiak Sciences Inc.
|
7775.20%
|
|
MRTX
|
Mirati Therapeutics Inc
|
95.18%
|
|
SANA
|
Sana Biotechnology, Inc.
|
7775.20%
|
|
XLRN
|
Acceleron Pharma Inc
|
100.00%
|
|
UTHR
|
United Therapeutics Corporation
|
87.92%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
7775.20%
|
|
ARNA
|
Arena Pharmaceuticals Inc
|
78.92%
|
|
EBS
|
Emergent BioSolutions Inc.
|
56.09%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
98.31%
|
|
IOVA
|
Iovance Biotherapeutics Inc
|
34.28%
|
|
BNTX
|
Biontech SE
|
84.37%
|
|
CVAC
|
CureVac NV
|
80.23%
|
|
SGEN
|
Seagen Inc
|
79.11%
|
|
TGTX
|
TG Therapeutics, Inc.
|
83.66%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
7775.20%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
69.33%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
89.81%
|
|
BHVN
|
Biohaven Ltd.
|
72.18%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
83.62%
|
|
FATE
|
Fate Therapeutics Inc
|
7775.20%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|